Sonja Mariotti Nesurini

Follow

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany	2017	Georg Isbary Thomas Staab Volker Eric Amelung Charalabos‐Markos Dintsios Christof Iking‐Konert Sonja Mariotti Nesurini Miriam Walter Jörg Ruof

Common Coauthors

Coauthor	Papers Together
Charalabos‐Markos Dintsios	1
Christof Iking‐Konert	1
Jörg Ruof	1
Georg Isbary	1
Thomas Staab	1
Miriam Walter	1
Volker Eric Amelung	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	The Strength of Association Between Surrogate End Points and Survival in Oncology	2015	Vinay Prasad Chul Kim Mauricio Burotto Andrae Vandross	1
+ PDF Chat	Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation	2014	Linus Jönsson Rickard Sandin Mattias Ekman Joakim Ramsberg Claudie Charbonneau Xin Huang Bengt Jønsson Milton C. Weinstein Michael Drummond	1
+	Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context	2014	Nicholas Latimer Keith R. Abrams Paul C. Lambert Michael J. Crowther Allan Wailoo James P. Morden Ron Akehurst Michael J. Campbell	1
+	Stopping clinical trials early for benefit: impact on estimation	2009	Boris Freidlin Edward L. Korn	1
+ PDF Chat	Stopping a trial early in oncology: for patients or for industry?	2009	Penelope A. Bradbury Ralph M. Meyer Joseph L. Pater Dongsheng Tu Lesley Seymour Lois E. Shepherd Elizabeth A. Eisenhauer	1
+	Stopping trials for efficacy: an almost unbiased view	2009	Steven N. Goodman	1
+	Methods for Adjusting for Bias Due to Crossover in Oncology Trials	2014	K. Jack Ishak Irina Proskorovsky Beata Korytowsky Rickard Sandin Sandrine Faivre Juan W. Valle	1
+ PDF Chat	Adjusting overall survival for treatment switches: commonly used methods and practical application	2013	Claire Watkins Xin Huang Nicholas Latimer Yiyun Tang Elaine WRIGHT	1
+ PDF Chat	The misguided ethics of crossover trials	2013	Vinay Prasad Christine Grady	1
+ PDF Chat	Stopping a trial early in oncology: for patients or for industry?	2008	Francesco Trotta Giovanni Apolone Silvio Garattini Giovanni Tafuri	1
+ PDF Chat	Trials stopped early for benefit? Not so fast!	2007	Alan C. Heffner Eric B Milbrandt Ramesh Venkataraman	1
+ PDF Chat	Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study	2011	James P. Morden Paul C. Lambert Nicholas Latimer Keith R. Abrams Allan Wailoo	1
+	Randomized Trials Stopped Early for Benefit	2005	Víctor M. Montori P.J. Devereaux Neill K. J. Adhikari Karen E. A. Burns C. Eggert Matthias Briel Christina Lacchetti Teresa W. Leung Elizabeth Darling Dianne Bryant	1
+	Stopping a trial early in oncology: for patients or for industry?	2008	John Whitehead Erik Cobo	1
+ PDF Chat	Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma	2016	Jose Diaz Cora N. Sternberg Faisal Mehmud Thomas E. Delea Nicholas Latimer Lini Pandite Robert J. Motzer	1
+	Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study	2013	Lijun Zhang Chia‐Wen Ko Shenghui Tang Rajeshwari Sridhara	1